Mediastinal Grey Zone Lymphoma Clinical Trial
Official title:
Mediastinal Grey Zone Lymphoma: Clinico-pathological Characteristics and Outcomes of 99 Patients From the LYSA
| Verified date | October 2016 |
| Source | Hospices Civils de Lyon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.
| Status | Completed |
| Enrollment | 99 |
| Est. completion date | June 2016 |
| Est. primary completion date | January 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - cases with an intermediate morphology and phenotype between CHL and PMBCL were included after central pathological review Exclusion Criteria: - Cases of CHL with partial CD20 expression or low expression in tumoral cells were excluded and considered as CD20-positive CHL - Exclusion of sequential form patients (with a diagnostic biopsy of PMBCL and a relapse biopsy of CHL or vise-versa) as they represent a biases for statistical analysis. |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre hospitalier Lyon sud | Pierre Bénite | Rhône Alpes |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | EFS in the global population of GZL | Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, a change of therapy that was not initially scheduled (radiotherapy, high-dose therapy with autologous stem cell transplantation and other unplanned treatments) or death from any cause. | EFS: Event Free Survival from date of randomization until the date of first documented progression, up to 130 months |